FDA Adverse Event Injury Summary report: N

EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE

MDR report key: 7469828 · Received April 27, 2018

Report

Report Number
2015691-2018-01572
Event Type
Injury
Date Received
April 27, 2018
Date of Event
April 1, 2018
Report Date
April 6, 2018
Manufacturer
EDWARDS LIFESCIENCES
Product Code
NPT
PMA / PMN Number
P140031
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

THE VALVE WAS NOT RETURNED TO EDWARDS LIFESCIENCES AS IT REMAINS IMPLANTED IN THE PATIENT.   PER THE INSTRUCTIONS FOR USE (IFU), PERMANENT OR TRANSIENT NEUROLOGICAL EVENTS INCLUDING STROKE ARE POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE TAVR PROCEDURE AND THE USE OF THE EDWARDS THV DEVICES.   ACCORDING TO LITERATURE REVIEW, AND AS DOCUMENTED IN A CLINICAL TECHNICAL SUMMARY WRITTEN BY EDWARDS LIFESCIENCES, STROKE IS RECOGNIZED IN THE LITERATURE AS A WELL-KNOWN COMPLICATION IN A SMALL NUMBER OF PATIENTS UNDERGOING TAVR.  RISK FACTORS CORRELATING WITH A NUMBER OF PATIENT CO-MORBIDITIES HAVE BEEN IDENTIFIED.  ALTHOUGH IN MANY CASES THE ROOT CAUSE OF THE EVENT IS UNABLE TO BE DETERMINED, STROKES DURING TAVR ARE UNDOUBTEDLY MULTIFACTORIAL, THE DOMINANT ETIOLOGY LIKELY BEING INTRA-PROCEDURE EMBOLIC EVENTS.  A TRANSCRANIAL DOPPLER STUDY DURING TAVR DEMONSTRATED THAT THE MAJORITY OF PROCEDURAL EMBOLIC EVENTS OCCURRED DURING BALLOON VALVULOPLASTY, MANIPULATION OF CATHETERS ACROSS THE AORTIC VALVE, AND VALVE IMPLANTATION.   AN ANALYSIS IN PATIENTS UNDERGOING VALVE SURGERY REVEALED FOUR BASELINE CHARACTERISTICS AND TWO PROCEDURAL EVENTS THAT WERE ASSOCIATED WITH EARLY POSTPROCEDURE STROKE: FEMALE SEX, EF < 30%, DIABETES, AGE OLDER THAN 70 YEARS, BYPASS PROCEDURE TIME> 120 MIN, AND CALCIFICATION OF THE ASCENDING AORTA.  PREDICTORS OF LATE STROKE HAVE INCLUDED FEMALE SEX, AGE OLDER THAN 75 YEARS, ATRIAL FIBRILLATION, AND A HISTORY OF OR CURRENT SMOKING.  THERE WERE NO IMPORTANT DIFFERENCES IN THE FREQUENCY OF LATE STROKES BETWEEN TAVR AND AVR PATIENTS.  AFTER TAVR, THERE APPEARS TO BE A MORE SIGNIFICANT PROPORTION OF EARLY STROKES OCCURRING < 24 H POST-PROCEDURE, BUT TAVR PATIENTS WITH MULTIPLE CO MORBIDITIES ARE PROBABLY AT HIGHER RISK OF BOTH EARLY AND LATE STROKES.   IN THIS CASE, THERE WAS NO ALLEGATION OR INDICATION A DEVICE MALFUNCTION CONTRIBUTED TO THIS ADVERSE EVENT.  THE CAUSE OF THE STROKE IS UNKNOWN, HOWEVER, MAY BE DUE TO PATIENT FACTORS (NOT PROVIDED) OR THE MECHANISMS DESCRIBED ABOVE.   THE IFU AND TRAINING MANUALS HAVE BEEN REVIEWED AND NO INADEQUACIES HAVE BEEN IDENTIFIED WITH REGARDS TO WARNINGS, CONTRAINDICATIONS, AND THE DIRECTIONS/CONDITIONS FOR THE SUCCESSFUL USE OF THE DEVICE.  COMPLAINT HISTORIES FOR ALL REPORTED EVENTS ARE REVIEWED AGAINST TRENDING CONTROL LIMITS ON A MONTHLY BASIS, AND ANY EXCURSIONS ABOVE THE CONTROL LIMITS ARE ASSESSED AND DOCUMENTED AS PART OF THIS MONTHLY REVIEW.  NO CORRECTIVE OR PREVENTATIVE ACTIONS ARE REQUIRED.

Additional Manufacturer Narrative · 1

DATE OF EVENT IS UNKNOWN. INVESTIGATION IS ONGOING. BIBLIOGRAPHY EITAN, ET AL ¿DOES VALVE IN VALVE TAVR CARRY A HIGHER RISK FOR DIFFUSION-WEIGHTED MRI BRAIN LESIONS IN COMPARE TO NATIVE VALVE TAVI?¿.  STUDY PRESENTED AT: DGK 2018. PROCEEDING S OF THE 84TH ANNUAL MEETING OF THE GERMAN SOCIETY OF CARDIOLOGY.  2018 APR-5-8, MANNHEIM, BADEN-WURTTEMBERG, GERMANY.

Description of Event or Problem · 1

AS REPORTED BY THE EDWARDS AFFILIATE IN (B)(4), DURING THE CONGRESS DGK 2018 ¿ 84TH ANNUAL MEETING OF THE GERMAN SOCIETY OF CARDIOLOGY ¿  IT WAS PRESENTED THE STUDY ¿DOES VALVE IN VALVE TAVR CARRY A HIGHER RISK FOR DIFFUSION-WEIGHTED MRI BRAIN LESIONS IN COMPARE TO NATIVE VALVE TAVI?¿.  THE STUDY INCLUDED 178 SAPIEN 3 PATIENTS.   ACCORDING TO THE PRESENTATION, ONE PATIENT WAS REPORTED TO HAVE EXPERIENCED A STROKE AFTER THE VALVE IN VALVE TAVI.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
310437 EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT EDWARDS LIFESCIENCES 9600TFX

Patients

Seq Age Sex Outcome Treatment
1 Other| R